A bill to revise and extend health workforce programs under title VII of the Public Health Service Act.
Summary
S.4110 is an early-stage authorization bill reauthorizing health workforce programs under the Public Health Service Act. It authorizes funding levels for FY2026-2030, but actual spending requires a separate appropriations process. The bill has no direct corporate beneficiaries and no market impact at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.4110 is a procedural authorization bill reauthorizing health workforce programs with modest funding increases.
- 2.No actual money is allocated—spending requires separate appropriations bills.
- 3.No publicly traded companies are direct beneficiaries; the bill primarily impacts non-profit academic institutions.
- 4.The bill is in early legislative stages with minimal momentum and no market impact.
Market Implications
No market implications at this time. The bill is an early-stage authorization affecting non-profit academic health centers, not publicly traded companies. No stock-level impact is anticipated unless the bill advances with amendments adding corporate beneficiaries or direct procurement provisions.
Full Analysis
- WHAT HAPPENED: On March 17, 2026, Senator Reed (D-RI) introduced S.4110, the 'EMPOWER for Health Act,' to reauthorize and incrementally increase funding for health professions workforce programs under Title VII of the Public Health Service Act. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. It has one cosponsor (Senator Murkowski, R-AK) and is in the earliest legislative stage. 2) THE MONEY TRAIL: This is an authorization bill, not an appropriations bill. It sets maximum funding levels for FY2026-2030 for specific programs (e.g., Section 736(i) authorizes $28.422M/year for health professions education; Section 740(a) authorizes $55.014M/year for scholarships). These are ceiling amounts. No actual money is allocated—separate appropriations bills must be passed each year. The total authorized amounts across all sections sum to approximately $265M annually, a modest increase over the previous FY2021-2025 authorization levels. 3) STRUCTURAL WINNERS AND LOSERS: The funding flows to academic health centers, teaching hospitals, and health professions schools via grants. No publicly traded company is a direct beneficiary. For-profit healthcare education companies (e.g., $ATGE, $LOPE, $STRA) are not referenced in the bill—it focuses on Title VII non-profit and public institutions. No tickers meet the causal chain threshold. 4) COMPETITIVE LANDSCAPE: The bill primarily affects grant-seeking academic institutions, not for-profit entities. Should it advance and be funded through appropriations, academic medical centers and medical schools could see incremental grant increases. However, with a single primary sponsor, one cosponsor, and early-stage status, legislative momentum is minimal. 5) TIMELINE: The bill must clear the HELP committee, pass the Senate, pass the House (no companion bill identified), and be signed into law. Even if enacted, agencies (HRSA) must implement rulemaking, and annual appropriations must pass. This is a multi-year process with no near-term market implications.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TSS-JCC LLC: $22.6M Department of Health and Human Services Contract
Keep Public Funds in Public Schools Act
A bill to amend the Higher Education Act of 1965 to provide for institutional ineligibility based on low cohort repayment rates and to require risk-sharing payments of institutions of higher education.
Critical Industry Skills Act
A SMART Act
Change of Ownership and Conversion Improvement Act
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.